Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024

Company Overview - Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on the discovery, development, and commercialization of genetic medicines for diseases with high unmet medical needs [3] - The company's first commercial product, VYJUVEK®, is the first-ever redosable gene therapy and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa [3] - Krystal Biotech is advancing a robust pipeline of investigational genetic medicines across various fields including respiratory, oncology, dermatology, ophthalmology, and aesthetics [3] Upcoming Financial Results - The company will report its second quarter 2024 financial results on August 5, 2024, prior to the opening of U.S. markets [1] - A conference call and webcast will be hosted by the company's management at 8:30 am ET on the same day to discuss the financial results and provide a business update [1] Access to Information - Investors and the general public can access the live webcast through a provided link [2] - A replay of the webcast will be available for 30 days on the company's website for those unable to listen live [2]